The SLIT3 Antibody, FITC conjugated is a fluorescently labeled rabbit polyclonal antibody designed to detect the Slit Homolog 3 (SLIT3) protein, a glycoprotein involved in axon guidance, angiogenesis, and tissue remodeling. FITC (fluorescein isothiocyanate) conjugation enables visualization under fluorescence microscopy, making it ideal for immunofluorescence studies.
Fluorescence Detection: FITC emission at 515 nm allows precise localization of SLIT3 in cellular or tissue sections.
Cross-Reactivity: Limited to human SLIT3, though homology exists with other species (e.g., mouse, rat) .
SLIT3 is a potent angiogenic factor that promotes endothelial cell proliferation and migration. The FITC-conjugated antibody has been used to:
Visualize SLIT3 expression in endothelial cells and vascular smooth muscle cells (VSMCs) .
Track SLIT3 secretion in co-culture systems (e.g., endothelial cells and fibroblasts) .
Monitor SLIT3-mediated angiogenesis in models of tissue repair or cancer .
SLIT3 regulates fibrillar collagen synthesis in fibroblasts. The antibody aids in:
Studying SLIT3’s role in myocardial fibrosis and ventricular remodeling .
Assessing therapeutic potential of targeting SLIT3 in fibrotic diseases (e.g., pulmonary fibrosis, liver cirrhosis) .
In brown adipose tissue (BAT), SLIT3 fragments coordinate angiogenesis and sympathetic innervation. The FITC-conjugated antibody enables:
Mapping SLIT3 expression in adipocyte progenitors and endothelial cells during cold-induced thermogenesis .
Analyzing proteolytic processing of SLIT3 into functional fragments .
The table below compares the FITC-conjugated antibody with other SLIT3 antibodies from diverse sources:
EC Proliferation: SLIT3 stimulates endothelial cell mitosis at concentrations comparable to VEGF .
Vascular Expansion: SLIT3-deficient mice exhibit reduced CD31hiEMCNhi endothelium, critical for osteogenesis and tissue repair .
Collagen Synthesis: Global SLIT3 deficiency reduces type I/III collagen expression and alleviates pressure overload-induced cardiac fibrosis .
Therapeutic Target: SLIT3 inhibition may mitigate adverse ventricular remodeling in heart failure .